Gossamer Bio Q2 net loss $56.5M; seralutinib Phase 2 readout on track for Nov/Dec 2022

Gossamer Bio, Inc.

2022-Q2 EPS reported -$1.50

Net loss of $56.5M ($0.74/share) vs $59.8M ($0.80/share) in Q2 2021.
Cash, equivalents & marketable securities $222.2M as of June 30; pro forma $342M after $120M July 2022 private placement.
Seralutinib Phase 2 TORREY topline data expected second half November or first half December 2022.
GB5121 Phase 1b/2 STAR CNS study in PCNSL dosed first patient.
Commencing investment in registrational Phase 3 program for seralutinib targeted for Q3 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.